队列
肿瘤科
医学
接收机工作特性
内科学
小RNA
阶段(地层学)
食管鳞状细胞癌
队列研究
比例危险模型
癌症
生物
基因
遗传学
古生物学
作者
Kai Liu,Yusheng Lin,Yujie Zhou,Xi Xiong,Lu Wang,Junkuo Li,Fuyou Zhou,Ye Guo,Shaobin Chen,Yuping Chen,Hui Tang,Xiaoyu Qiu,Songwang Cai,Dianzheng Zhang,Edwin Bremer,Sai‐Ching Jim Yeung,Hao Zhang
标识
DOI:10.1053/j.gastro.2023.06.021
摘要
Background and aims Early detection of esophageal squamous cell carcinoma (ESCC) will facilitate curative treatment. We aimed to establish a micro-RNA (miRNA) signature derived from salivary extracellular vesicles and particles (EVPs) for early ESCC detection and prognostication. Methods Salivary EVP miRNA expression was profiled in a pilot cohort (n=54) using microarray. Area under the receiver-operator characteristic curve (AUROC) and lasso regression analyses were used to prioritize miRNAs that discriminated ESCC patients from controls. Using quantitative reverse transcription-polymerase chain reaction, the candidates were measured in a discovery cohort (n=72) and cell lines. The prediction models for the biomarkers were derived from a training cohort (n=342) and validated in an internal cohort (n=207) and an external cohort (n=226). Results The microarray analysis identified 7 miRNAs for distinguishing ESCC patients from control subjects. Since one was not always detectable in the discovery cohort and cell lines, the other 6 miRNAs formed a panel. A signature of this panel accurately identified all-stage ESCC patients in the training cohort (AUROC=0.968) and was successfully validated in two independent cohorts. Importantly, this signature could distinguish early-stage (stage Ⅰ/ Ⅱ) ESCC patients from control subjects in the training cohort (AUROC=0.969, sensitivity=92.00%, specificity=89.17%), internal (sensitivity=90.32%, specificity=91.04%) and external (sensitivity=91.07%, specificity=88.06%) validation cohorts. Moreover, a prognostic signature based on the panel was established and efficiently predicted the high-risk cases with poor progression-free survival and overall survival. Conclusion The salivary EVP-based 6-miRNA signature can serve as noninvasive biomarkers for early detection and risk stratification of ESCC. Chinese Clinical Trial Registry, ChiCTR2000031507.
科研通智能强力驱动
Strongly Powered by AbleSci AI